877239-08-2

Usage

Uses

Used in Chemical Biology:
Trityl-PEG9-Azide is used as a building block for the synthesis of bioconjugates and probes for chemical biology research. The azide group allows for efficient and selective ligation through Click Chemistry, enabling the rapid and modular assembly of complex molecules and the development of novel probes for biological studies.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Trityl-PEG9-Azide is used as a component in the design of drug delivery systems. The PEG spacer improves the solubility and stability of drug conjugates, while the trityl-protected ester can be selectively removed under specific conditions to release the active drug. This feature is particularly useful for the development of targeted therapies and controlled release systems.
Used in Bioconjugation:
Trityl-PEG9-Azide is employed as a versatile linker for bioconjugation in various applications, such as the attachment of biologically active molecules to nanoparticles, polymers, or other surfaces. The trityl group can be removed under mild conditions, allowing for the controlled release of the conjugated molecule, while the PEG spacer provides steric stabilization and reduces non-specific interactions.
Used in Materials Science:
In materials science, Trityl-PEG9-Azide is used as a functional component in the development of smart materials and coatings. The azide group can be utilized for Click Chemistry-based surface modifications, enabling the covalent attachment of various functional groups or biomolecules to create stimuli-responsive or bioactive materials.
Overall, Trityl-PEG9-Azide is a valuable reagent in the fields of chemical biology, drug delivery, bioconjugation, and materials science, owing to its unique combination of a trityl-protected ester, an azide group for Click Chemistry, and a hydrophilic PEG spacer.

Upstream product

• 76-84-6 triphenylmethyl alcohol 
• 105589-77-3 2-(2-trityloxyethoxy)ethanol 
• 146462-58-0 2-<2-(triphenylmethoxy)ethoxy>ethyl methanesulfonate 
• 127999-16-0 19-(triphenylmethyl)-1,4,7,10,13,16,19-heptaoxanonadecanol 
• 745048-16-2 19,19,19-triphenyl-3,6,9,12,15,18-hexaoxanonadec-1-ylmethanesulfonate 
• 125274-14-8 2-{2-[2-(2-{2-[2-(2-{2-[2-(2-trityloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethanol 
• 134179-43-4 11-azide-1-{(methylsulfonyl)oxy}-3,6,9-trioxaundecane 
• 352439-34-0 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl methanesulfonate 
• 86770-69-6 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 2615-15-8 pentaethylene glycol 
• 112-60-7 Tetraethylene glycol 

Downstream Products

• 129449-09-8 29-amino-3,6,9,12,15,18,21,24,27-nonaoxanonacosan-1-ol 

Relevant academic research and scientific papers

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

GALACTOSE DERIVATIVE, DRUG CARRIER AND MEDICINAL COMPOSITION

The object of the invention is to provide a novel and useful galactose derivative constituting a drug carrier by which a medicine can be efficiently transferred into the liver, a drug carrier comprising the derivative, and a pharmaceutical composition comprising the carrier and a medicine. The present invention relates to a galactose derivative made up of galactose, a suitable spacer and a certain lipid, a drug carrier comprising the derivative and a cationic lipid, and a pharmaceutical composition comprising the carrier and a medicine (preferably a double strand RNA, a double strand DNA, an oligo nucleic acid) .

Synthesis of a series of oligo(ethylene glycol)-terminated alkanethiol amides designed to address structure and stability of biosensing interfaces

A strategy for the synthesis of a series of closely related oligo(ethylene glycol)-terminated alkanethiol amides (principally HS(CH2)mCONH(CH2CH2O) nH; m = 2, 5, 11, 15, n = 1, 2, 4, 6, 8, 10, 12) and analogous esters has been developed. These compounds were made to study the structure and stability of self-assembled monolayers (SAMs) on gold in the prospect of designing new biosensing interfaces. For this purpose, monodisperse heterofunctional oligo(ethylene glycols) with up to 12 units were prepared. Selective monoacylation of the symmetrical tetra- and hexa(ethylene glycol) diols as their mesylates with the use of silver(I) oxide was performed. The synthetic approach was based on carbodiimide couplings of various oligo(ethylene glycol) derivatives to ω-(acetylthio) carboxylic acids via a terminal amino or hydroxyl function. SAM structures on gold were studied with respect to thickness, wettability (water contact angles ～30°), and conformation. A good fit was obtained for the relation between monolayer thickness (d) and the number of units in the oligo(ethylene glycol) chain (n): d = 2.8n + 21.8 (A). Interestingly, the corresponding infrared spectroscopy analysis showed a dramatic change in conformation of the oligomeric chains from all-trans (n = 4) to helical (n ≥ 6) conformation. A crystalline helical structure was observed in the SAMs for n > 6.